JP6453063B2 - アジュバント組成物 - Google Patents

アジュバント組成物 Download PDF

Info

Publication number
JP6453063B2
JP6453063B2 JP2014244421A JP2014244421A JP6453063B2 JP 6453063 B2 JP6453063 B2 JP 6453063B2 JP 2014244421 A JP2014244421 A JP 2014244421A JP 2014244421 A JP2014244421 A JP 2014244421A JP 6453063 B2 JP6453063 B2 JP 6453063B2
Authority
JP
Japan
Prior art keywords
nucleic acid
cancer
rna
stranded
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014244421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016108250A (ja
JP2016108250A5 (cg-RX-API-DMAC7.html
Inventor
瀬谷　司
司 瀬谷
松本　美佐子
美佐子 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2014244421A priority Critical patent/JP6453063B2/ja
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Priority to EP15865520.9A priority patent/EP3228322B8/en
Priority to PCT/JP2015/083825 priority patent/WO2016088784A1/ja
Priority to US15/531,671 priority patent/US10105385B1/en
Priority to AU2015356078A priority patent/AU2015356078B2/en
Priority to CA2969024A priority patent/CA2969024C/en
Priority to CN201580065778.3A priority patent/CN106999573B/zh
Publication of JP2016108250A publication Critical patent/JP2016108250A/ja
Publication of JP2016108250A5 publication Critical patent/JP2016108250A5/ja
Application granted granted Critical
Publication of JP6453063B2 publication Critical patent/JP6453063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014244421A 2014-12-02 2014-12-02 アジュバント組成物 Active JP6453063B2 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物
PCT/JP2015/083825 WO2016088784A1 (ja) 2014-12-02 2015-12-01 アジュバント組成物
US15/531,671 US10105385B1 (en) 2014-12-02 2015-12-01 Adjuvant composition
AU2015356078A AU2015356078B2 (en) 2014-12-02 2015-12-01 Adjuvant composition
EP15865520.9A EP3228322B8 (en) 2014-12-02 2015-12-01 Adjuvant composition
CA2969024A CA2969024C (en) 2014-12-02 2015-12-01 Adjuvant composition
CN201580065778.3A CN106999573B (zh) 2014-12-02 2015-12-01 佐剂组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014244421A JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物

Publications (3)

Publication Number Publication Date
JP2016108250A JP2016108250A (ja) 2016-06-20
JP2016108250A5 JP2016108250A5 (cg-RX-API-DMAC7.html) 2018-01-25
JP6453063B2 true JP6453063B2 (ja) 2019-01-16

Family

ID=56091725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014244421A Active JP6453063B2 (ja) 2014-12-02 2014-12-02 アジュバント組成物

Country Status (7)

Country Link
US (1) US10105385B1 (cg-RX-API-DMAC7.html)
EP (1) EP3228322B8 (cg-RX-API-DMAC7.html)
JP (1) JP6453063B2 (cg-RX-API-DMAC7.html)
CN (1) CN106999573B (cg-RX-API-DMAC7.html)
AU (1) AU2015356078B2 (cg-RX-API-DMAC7.html)
CA (1) CA2969024C (cg-RX-API-DMAC7.html)
WO (1) WO2016088784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020473B2 (en) * 2016-06-24 2021-06-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US11065331B2 (en) 2016-07-27 2021-07-20 Advanced Innovation Development Co. Ltd. Immune adjuvant for cancer
CN109963584B (zh) 2016-09-06 2024-03-15 豪夫迈·罗氏有限公司 结合mhc的肽阵列及其使用方法
AU2023389310A1 (en) 2022-12-05 2025-06-19 Aomori Yamada Gakuen Educational Corporation Nucleic acid adjuvant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177927C (zh) * 1998-03-26 2004-12-01 惠氏控股有限公司 引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
US9090650B2 (en) 2010-07-28 2015-07-28 National University Corporation Hokkaido University Nucleic acid having adjuvanticity and use thereof
CN102000330B (zh) * 2010-09-14 2012-08-29 中国人民解放军第二军医大学 一种核酸疫苗佐剂及其构建方法

Also Published As

Publication number Publication date
WO2016088784A1 (ja) 2016-06-09
EP3228322B8 (en) 2019-06-19
CN106999573B (zh) 2021-10-19
CN106999573A (zh) 2017-08-01
EP3228322A1 (en) 2017-10-11
JP2016108250A (ja) 2016-06-20
EP3228322B1 (en) 2019-04-10
US20180280425A1 (en) 2018-10-04
CA2969024A1 (en) 2016-06-09
AU2015356078A1 (en) 2017-06-29
AU2015356078B2 (en) 2021-09-16
CA2969024C (en) 2022-05-24
EP3228322A4 (en) 2018-05-30
US10105385B1 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
JP5871212B2 (ja) アジュバント活性を有する新規核酸およびその利用
RU2768829C2 (ru) Противораковые рнк-вакцины
US20200254086A1 (en) Efficacious mrna vaccines
JP2021512090A (ja) 免疫細胞に薬剤を送達するための組成物及び方法
JP2022501336A (ja) ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物
US11931409B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
BR112019020001A2 (pt) linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
JP6453063B2 (ja) アジュバント組成物
WO2023014974A1 (en) Double stranded mrna vaccines
CN118265791A (zh) 用于cGAS-STING和STAT3通路调节以对癌症进行免疫治疗性治疗的球形核酸
WO2020116537A1 (ja) がん処置用ＲＮＡｉ分子
JP2025536260A (ja) 細胞透過性抗体の組成物および使用方法
WO2025158069A1 (en) CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
NZ793715A (en) RNA cancer vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170901

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181212

R150 Certificate of patent or registration of utility model

Ref document number: 6453063

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250